SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Di

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adj

Related stories